相关实验视频

Updated: Jun 14, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

针对儿科发病多发性硬化症的抗CD20疗法:系统性审查

Masoud Etemadifar¹, Hosein Nouri², Nahad Sedaghat²

¹Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Multiple sclerosis and related disorders

|September 7, 2024

概括

抗CD20疗法通过减少复发和病变,在儿科多发性硬化症 (MS) 中显示出有效性. 虽然通常是安全的,但潜在的不良事件需要仔细考虑,特别是对于高度活跃的病例.

科学领域:

神经学神经学
免疫学免疫学免疫学

背景情况:

儿科发病多发性硬化症 (POMS) 占MS病例的3-5%.
抗CD20疗法已在成年MS中建立,并越来越多地考虑POMS.

研究的目的:

审查最新关于抗CD20疗法在POMS中的安全性和有效性的证据.

主要方法:

在PubMed,Scopus和Web of Science的系统文献搜索到2024年7月.
选了832项遵循PRISMA指南的研究.
来自12项rituximab研究和6项ocrelizumab研究的数据综合.

主要成果:

抗CD20疗法显著减少POMS患者的复发和病变.
没有证据表明疾病活跃,特别是在高度活跃的POMS中.
潜在的不良事件与抗CD20疗法有关;关于残疾积累的数据正在等待.

结论:

抗CD20疗法是POMS的一个可行的选择,特别是在高度活跃或抗平台治疗的病例中.
仔细监测不良事件是必要的.
需要对长期残疾结果进行进一步的研究.

关键词:

这是一个反CD2020的反CD20.这就是Ocrelizumab.这就是POMS的意义.儿科多发性硬化症儿童多发性硬化症里图西马布 (Rituximab) 是一种药物.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...